# US 2009/0269340 A1 · Antibodies to oncostatin m receptor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0269340 A1
- Document ID: US20090269340A1
- Status: Published application
- Kind: A1
- Application number: 12/497,439
- Filed: 2009-07-02
- Published: 2009-10-29
- Earliest claimed: 2005-02-03
- Assignees: MacroGenics, Inc.
- Inventors: Jennie P. MATHER; Penelope E. Roberts
- Web page: https://patentgrep.com/patent/US20090269340A1

## CPC

- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- C07K 16/248: {IL-6}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 16/30: from tumour cells
- G01N 33/575: for cancer
- A61K 2039/505: {comprising antibodies}
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- G01N 2333/715: for cytokines; for lymphokines; for interferons
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides characterization of the disease and cancer-associated antigen, OSM-R.beta. The invention also provides modulators of OSM-R.beta, including a family of monoclonal antibodies that bind to antigen OSM-R.beta, and methods of diagnosing and treating various human cancers and diseases associated with OSM-R.beta.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim at position 2

16: A method for delivering a therapeutic agent to a cancer cell comprising administering a composition comprising an anti-OSM-R.beta antibody that specifically binds to OSM-R.beta, wherein the anti-OSM-R.beta antibody is associated with the therapeutic agent, wherein the cancer cell is selected from the group consisting of cancer cells from adrenal gland tumors, AIDS-associated cancers, alveolar soft part sarcoma, astrocytic tumors, bladder cancer (squamous cell carcinoma and transitional cell carcinoma), bone cancer (adamantinoma, aneurismal bone cysts, osteochondroma, osteosarcoma), brain and spinal cord cancers, metastatic brain tumors, breast cancer, carotid body tumors, cervical cancer, chondrosarcoma, chordoma, chromophobe renal cell carcinoma, clear cell carcinoma, colon cancer, colorectal cancer, cutaneous benign fibrous histiocytomas, desmoplastic small round cell tumors, ependymomas, Ewing's tumors, extraskeletal myxoid chondrosarcoma, fibrogenesis imperfecta ossium, fibrous dysplasia of the bone, gallbladder and bile duct cancers, gestational trophoblastic disease, germ cell tumors, head and neck cancers, islet cell tumors, Kaposi's Sarcoma, kidney cancer (nephroblastoma, papillary renal cell carcinoma), leukemias, lipomalbenign lipomatous tumors, liposarcoma/malignant lipomatous tumors, liver cancer (hepatoblastoma, hepatocellular carcinoma), lymphomas, lung cancers (small cell carcinoma, adenocarcinoma, squamous cell carcinoma, large cell carcinoma etc.), medulloblastoma, melanoma, meningiomas, multiple endocrine neoplasia, multiple myeloma, myelodysplastic syndrome, neuroblastoma, glioblastoma, neuroendocrine tumors, ovarian cancer, pancreatic cancers, papillary thyroid carcinomas, parathyroid tumors, pediatric cancers, peripheral nerve sheath tumors, phaeochromocytoma, pituitary tumors, prostate cancer, posterious unveal melanoma, rare hematologic disorders, renal metastatic cancer, rhabdoid tumor, rhabdomysarcoma, sarcomas, skin cancer, soft-tissue sarcomas, squamous cell cancer, stomach cancer, synovial sarcoma, testicular cancer, thymic carcinoma, thymoma, thyroid metastatic cancer, and uterine cancers (carcinoma of the cervix, endometrial carcinoma, and leiomyoma).

### Claim at position 3 (depends on 16)

17: The method of claim 16, wherein the anti-OSM-R.beta antibody is the monoclonal antibody expressed by the hybridoma having ATCC No. PTA-6511, or an antigen-binding fragment thereof.

### Claim at position 4

18: A method of inhibiting growth of cancer cells in an individual comprising administering to the individual an effective amount of a composition comprising an anti-OSM-R.beta antibody that specifically binds to OSM-R.beta to the individual, wherein the cancer cells are selected from the group consisting of cancer cells from adrenal gland tumors, AIDS-associated cancers, alveolar soft part sarcoma, astrocytic tumors, bladder cancer (squamous cell carcinoma and transitional cell carcinoma), bone cancer (adamantinoma, aneurismal bone cysts, osteochondroma, osteosarcoma), brain and spinal cord cancers, metastatic brain tumors, breast cancer, carotid body tumors, cervical cancer, chondrosarcoma, chordoma, chromophobe renal cell carcinoma, clear cell carcinoma, colon cancer, colorectal cancer, cutaneous benign fibrous histiocytomas, desmoplastic small round cell tumors, ependymomas, Ewing's tumors, extraskeletal myxoid chondrosarcoma, fibrogenesis imperfecta ossium, fibrous dysplasia of the bone, gallbladder and bile duct cancers, gestational trophoblastic disease, germ cell tumors, head and neck cancers, islet cell tumors, Kaposi's Sarcoma, kidney cancer (nephroblastoma, papillary renal cell carcinoma), leukemias, lipomalbenign lipomatous tumors, liposarcoma/malignant lipomatous tumors, liver cancer (hepatoblastoma, hepatocellular carcinoma), lymphomas, lung cancers (small cell carcinoma, adenocarcinoma, squamous cell carcinoma, large cell carcinoma etc.), medulloblastoma, melanoma, meningiomas, multiple endocrine neoplasia, multiple myeloma, myelodysplastic syndrome, neuroblastoma, glioblastoma, neuroendocrine tumors, ovarian cancer, pancreatic cancers, papillary thyroid carcinomas, parathyroid tumors, pediatric cancers, peripheral nerve sheath tumors, phaeochromocytoma, pituitary tumors, prostate cancer, posterious unveal melanoma, rare hematologic disorders, renal metastatic cancer, rhabdoid tumor, rhabdomysarcoma, sarcomas, skin cancer, soft-tissue sarcomas, squamous cell cancer, stomach cancer, synovial sarcoma, testicular cancer, thymic carcinoma, thymoma, thyroid metastatic cancer, and uterine cancers (carcinoma of the cervix, endometrial carcinoma, and leiomyoma).

### Claim at position 5 (depends on 32)

19: The method of claim 32, wherein the therapeutic agent is delivered into the cancer cells.

### Claim at position 6 (depends on 18)

20: The method of claim 18, wherein the anti-OSM-R.beta antibody is the monoclonal antibody expressed by the hybridoma having ATCC No. PTA-6511, or an antigen-binding fragment thereof.

### Claim at position 7

21-23. (canceled)

### Claim at position 8 (depends on 16)

24: The method of claim 16, wherein the anti-OSM-R.beta antibody comprises the three complementarity determining regions from the heavy chain and the three complementarity determining regions from the light chain of the monoclonal antibody produced by the hybridoma having ATCC No. PTA-6511.

### Claim at position 9 (depends on 24)

25: The method of claim 24, wherein the anti-OSM-R.beta antibody is a humanized antibody.

### Claim at position 10 (depends on 24)

26: The method of claim 24, wherein the anti-OSM-R.beta antibody is a chimeric antibody comprising the heavy chain and the light chain variable regions of the monoclonal antibody produced by the hybridoma having ATCC No. PTA-6511.

### Claim at position 11 (depends on 26)

27: The method of claim 26, wherein the chimeric antibody comprises a heavy chain constant region and a light chain constant region from a human antibody.

### Claim at position 12 (depends on 24)

28: The method of claim 24, wherein the anti-OSM-R.beta antibody is linked to the therapeutic agent.

### Claim at position 13 (depends on 24)

29: The method of claim 24, wherein the anti-OSM-R.beta antibody is an antigen-binding fragment selected from the group consisting of a Fab, a Fab′, a F(ab′)2 and a Fv; and wherein the antigen-binding fragment retains the binding specificity of the monoclonal antibody expressed by the hybridoma having ATCC No. PTA-6511.

### Claim at position 14 (depends on 16)

30: The method of claim 16, wherein the anti-OSM-R.beta antibody comprises the heavy chain variable region of the monoclonal antibody expressed by the hybridoma having ATCC No. PTA-6511.

### Claim at position 15 (depends on 16)

31: The method of claim 16, wherein the anti-OSM-R.beta antibody comprises the light chain variable region of the monoclonal antibody expressed by the hybridoma having ATCC No. PTA-6511.

### Claim at position 16 (depends on 18)

32: The method of claim 18, wherein the anti-OSM-R.beta antibody is associated with a therapeutic agent.

### Claim at position 17 (depends on 32)

33: The method of claim 32, wherein the anti-OSM-R.beta antibody is linked to the therapeutic agent.

### Claim at position 18 (depends on 18)

34: The method of claim 18, wherein the anti-OSM-R.beta antibody comprises the three complementarity determining regions from the heavy chain and the three complementarity determining regions from the light chain of the monoclonal antibody expressed by the hybridoma having ATCC No. PTA-6511.

### Claim at position 19 (depends on 34)

35: The method of claim 34, wherein the anti-OSM-R.beta antibody is a humanized antibody.

### Claim at position 20 (depends on 34)

36: The method of claim 34, wherein the anti-OSM-R.beta antibody is a chimeric antibody comprising the heavy chain and the light chain variable regions of the monoclonal antibody expressed by the hybridoma having ATCC No. PTA-6511.

### Claim at position 21 (depends on 36)

37: The method of claim 36, wherein the chimeric antibody comprises a heavy chain constant region and a light chain constant region from a human antibody.

### Claim at position 22 (depends on 34)

38: The method of claim 34, wherein the anti-OSM-R.beta antibody is an antigen-binding fragment selected from the group consisting of a Fab, a Fab′, a F(ab′)2 and a Fv; and wherein the antigen-binding fragment retains the binding specificity of the monoclonal antibody produced by the hybridoma having ATCC No. PTA-6511.

### Claim at position 23 (depends on 18)

39: The method of claim 18, wherein the anti-OSM-R.beta antibody comprises the heavy chain variable region of the monoclonal antibody expressed by the hybridoma having ATCC No. PTA-6511.

### Claim at position 24 (depends on 18)

40: The method of claim 18, wherein the anti-OSM-R.beta antibody comprises the light chain variable region of the monoclonal antibody expressed by the hybridoma having ATCC No. PTA-6511.
